Lite Strategy Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
LITS
- Investments
-
4
- Share Price
-
$0.80
- (As of Friday Closing)
Lite Strategy General Information
Description
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
Contact Information
Website
www.litestrategy.comCorporate Office
- 9920 Pacific Heights Boulevard
- Suite 150
- San Diego, CA 92121
- United States
Corporate Office
- 9920 Pacific Heights Boulevard
- Suite 150
- San Diego, CA 92121
- United States
Lite Strategy Stock Performance
As of 20-Nov-2026, Lite Strategy’s stock price is $0.80. Its current market cap is $24M with 29.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.80 | $0.84 | $0.69 - $1.99 | $24M | 29.9M | 522K | -$1.38 |
Lite Strategy Financials Summary
As of 30-Sep-2026, Lite Strategy has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 34,432 | 21,757 | (4,015) | (25,496) |
| Revenue | 0 | 0 | 0 | 65,297 |
| EBITDA | (51,691) | (71,417) | (16,603) | 14,884 |
| Net Income | (51,488) | (71,150) | (15,945) | 17,778 |
| Total Assets | 58,401 | 42,692 | 18,285 | 41,375 |
| Total Debt | 0 | 0 | 0 | 0 |
Lite Strategy Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lite Strategy Comparisons
Industry
Financing
Details
Lite Strategy Competitors (81)
One of Lite Strategy’s 81 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Olema Oncology | Formerly VC-backed | San Francisco, CA | ||||
| TME Pharma | Formerly VC-backed | Berlin, Germany | ||||
| Elicio Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Lite Strategy Patents
Lite Strategy Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024173833-A1 | Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer | Inactive | 16-Feb-2023 | ||
| WO-2024137472-A2 | Combination therapies | Inactive | 19-Dec-2022 | ||
| WO-2024137472-A3 | Combination therapies | Inactive | 19-Dec-2022 | ||
| AU-2023228576-A1 | Combination therapy of pi3k inhibitor and pd-1 inhibitor | Pending | 01-Mar-2022 | ||
| EP-4486351-A1 | Combination therapy of pi3k inhibitor and pd-1 inhibitor | Pending | 01-Mar-2022 | A61K31/5377 |
Lite Strategy Signals
Lite Strategy Investments & Acquisitions (4)
Lite Strategy’s most recent deal was a Corporate with LitVM for . The deal was made on 18-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| LitVM | 18-Jun-2026 | Corporate | Software Development Applications | ||
| Presage Biosciences (anti-cancer drug candidate voruciclib) | 05-Sep-2017 | Corporate Asset Purchase | Buildings and Property | ||
| Pathway Therapeutics (Anticancer Drug) | 14-Aug-2013 | Merger/Acquisition | Biotechnology | ||
| S*Bio (Cancer Drug Rights) | 10-Aug-2012 | Corporate Asset Purchase | Buildings and Property |
Lite Strategy ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.7 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Lite Strategy Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| MEI Pharma (Rights, Title, Interest and Certain Assets Related to ME-344) | San Diego, CA |
Lite Strategy FAQs
-
When was Lite Strategy founded?
Lite Strategy was founded in 2000.
-
Where is Lite Strategy headquartered?
Lite Strategy is headquartered in San Diego, CA.
-
What is the size of Lite Strategy?
Lite Strategy has 5 total employees.
-
What industry is Lite Strategy in?
Lite Strategy’s primary industry is Drug Discovery.
-
Is Lite Strategy a private or public company?
Lite Strategy is a Public company.
-
What is Lite Strategy’s stock symbol?
The ticker symbol for Lite Strategy is LITS.
-
What is the current stock price of Lite Strategy?
As of 20-Nov-2026 the stock price of Lite Strategy is $0.80.
-
What is the current market cap of Lite Strategy?
The current market capitalization of Lite Strategy is $24M.
-
Who are Lite Strategy’s competitors?
Ayala Pharmaceuticals, Olema Oncology, TME Pharma, Elicio Therapeutics, and Adaptimmune Therapeutics are some of the 81 competitors of Lite Strategy.
-
What is Lite Strategy’s annual earnings per share (EPS)?
Lite Strategy’s EPS for 12 months was -$1.38.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process